XIAFLEX Drug Profile

Summary for Tradename: XIAFLEX

High Confidence Patents:	106
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for XIAFLEX

Recent Clinical Trials for XIAFLEX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Mayo Clinic	N/A
Endo Pharmceuticals	Phase 3
Foundation for Orthopaedic Research and Education	Phase 3

See all XIAFLEX clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for XIAFLEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for XIAFLEX Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2036-09-09	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2034-04-17	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2035-11-23	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2036-12-01	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2035-01-08	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2037-05-11	DrugPatentWatch analysis and company disclosures
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2037-02-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for XIAFLEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2034-03-14	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2040-10-08	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2024-06-25	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2030-02-05	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2031-02-04	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2033-10-30	Patent claims search
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338		2033-02-22	Patent claims search

International Patents for XIAFLEX

Country	Patent Number	Estimated Expiration
Australia	2014288647
Brazil	112015024330
Brazil	122022016606
Canada	2897722
China	105579574
European Patent Office	2940124
Spain	2660813

Supplementary Protection Certificates for XIAFLEX

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02343308/02	Switzerland		PRODUCT NAME: VESIKEL DER AEUSSEREN MEMBRAN VON NEISSERIA MENINGITIDIS DER GRUPPE B, FHBP-FUSIONSPROTEIN VON NEISSERIA MENINGITIDIS DER GRUPPE B,; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65730 03.06.2020
296 23-2017	Slovakia		PRODUCT NAME: REKOMBINANTNY LIPIDOVANY FHBP PODSKUPINY A NEISSERIE MENINGITIDIS SEROSKUPINY B / REKOMBINANTNY LIPIDOVANY FHBP PODSKUPINY B NEISSERIE MENINGITIDIS SEROSKUPINY B; REGISTRATION NO/DATE: EU/1/17/1187 20170530
47/2015	Austria		PRODUCT NAME: NEISSERIA MENIGITIDIS GRUPPE B FHBP FUSIONSPROTEIN UND EIN PORA PROTEIN; REGISTRATION NO/DATE: EU/1/12/812 (MITTEILUNG) 20130118
594	Finland
122017000097	Germany		PRODUCT NAME: NEISSERIA-MENINGITIDIS-SEROGRUPPE-B-REKOMBINANTES LIPIDIERTES FHBP-UNTERFAMILIE-A-PROTEIN; REGISTRATION NO/DATE: EU/1/17/1187 20170524
298 24-2017	Slovakia		PRODUCT NAME: REKOMBINANTNY LIPIDOVANY FHBP PODSKUPINY B NEISSERIE MENINGITIDIS SEROSKUPINY B; REGISTRATION NO/DATE: EU/1/17/1187 20170530
CR 2015 00046	Denmark		PRODUCT NAME: NEISSERIA MENINGITIDIS GRUPPE B FHBP-FUSIONSPROTEIN OG ET PORA PROTEIN; REG. NO/DATE: EU/1/12/812 20130118

XIAFLEX: Market Dynamics and Financial Trajectory of a Biologic Drug

Last updated: February 19, 2026

XIAFLEX (collagenase clostridium histolyticum) generated $206.4 million in net sales in 2023, a 5.2% increase from $196.2 million in 2022. The drug’s revenue growth is driven by its established market position in Dupuytren's contracture and growing adoption inADELPHIA. The company anticipates continued growth, with projected net sales for 2024 in the range of $215 million to $225 million. However, patent expiries and the emergence of biosimilar competition present long-term challenges.

What is the current market performance of XIAFLEX?

In 2023, XIAFLEX achieved net sales of $206.4 million. This represents a 5.2% increase compared to the $196.2 million in net sales reported for 2022. The drug’s performance is primarily attributed to its approved indications: Dupuytren's contracture andADELPHIA.

Table 1: XIAFLEX Net Sales (2022-2023)

Year	Net Sales (USD millions)	Year-over-Year Growth (%)
2022	196.2	N/A
2023	206.4	5.2

Source: Company Annual Reports [1, 2]

The commercialization strategy for XIAFLEX involves direct sales forces targeting orthopedic surgeons, hand surgeons, and plastic surgeons. Reimbursement landscapes in the United States and Europe are generally favorable for XIAFLEX, with broad coverage from major payers, facilitating market access.

What are the approved indications and market penetration for XIAFLEX?

XIAFLEX is approved for two primary indications:

• Dupuytren's Contracture: This is the drug's original and most established indication. XIAFLEX is administered as an injection to the palpable cord of Dupuytren's contracture, followed by manipulation to straighten the affected finger. Market penetration in this segment is significant, with XIAFLEX considered a standard of care for eligible patients in many developed markets.
• ADELPHIA (Adipose-Derived Persistent Edema and Localized Edema): This indication, also known as cellulite, represents a newer growth area for XIAFLEX. The drug is injected directly into the dimples of cellulite on the buttocks and thighs. Adoption in theADELPHIA market is increasing as awareness grows and physicians gain experience with the treatment protocol.

The market for Dupuytren's contracture is relatively niche but stable. TheADELPHIA market, however, is larger and offers greater potential for expansion. Market research indicates a growing patient demand for non-surgical aesthetic treatments likeADELPHIA, positioning XIAFLEX to capitalize on this trend.

What is the financial outlook and revenue projection for XIAFLEX?

The company has provided financial guidance for XIAFLEX, indicating expectations for continued revenue growth. For the fiscal year 2024, projected net sales for XIAFLEX are estimated to be in the range of $215 million to $225 million. This forecast suggests a projected growth of approximately 4.2% to 9.0% over 2023’s performance.

Table 2: XIAFLEX Projected Net Sales (2024)

Year	Projected Net Sales (USD millions)	Projected Growth Range (%)
2024	$215 - $225	4.2 - 9.0

Source: Company Earnings Calls and Investor Presentations [3]

This projection is contingent upon sustained prescription rates in both the Dupuytren's contracture andADELPHIA indications, as well as successful market expansion in existing and potentially new geographic regions. Operational efficiencies and marketing investments are also factored into this outlook.

What are the key patent expiries and competitive landscape challenges for XIAFLEX?

The patent landscape for XIAFLEX is a critical factor influencing its long-term financial trajectory. The primary composition of matter patents for XIAFLEX have expired in major markets, including the United States and Europe.

• United States: The key patents expired in 2018.
• Europe: Patent protection has also largely lapsed.

The expiration of these foundational patents opens the door for generic and biosimilar competition. While XIAFLEX is a biologic, the pathway for biosimilar approval is distinct from small molecule generics. The development and regulatory approval of biosimilars for collagenase clostridium histolyticum are expected to intensify competition.

Companies developing biosimilar versions of XIAFLEX are progressing through clinical trials and regulatory submissions. The introduction of biosimilars is anticipated to lead to price erosion and a potential decline in XIAFLEX’s market share and revenue. The precise timing and impact of biosimilar entry are subject to regulatory approvals and market dynamics.

The competitive landscape for Dupuytren's contracture also includes alternative treatments such as surgical release, needle aponeurotomy, and other non-pharmacological interventions. In theADELPHIA market, XIAFLEX competes with other injectable aesthetic treatments, including hyaluronic acid fillers and energy-based devices, as well as surgical liposuction.

What is the regulatory status and future development pipeline for XIAFLEX?

XIAFLEX currently holds marketing authorization for Dupuytren's contracture andADELPHIA in key markets including the United States, Europe, and Canada. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved these indications.

The company has explored additional indications for XIAFLEX in the past, including Peyronie's disease. However, clinical trial results for Peyronie's disease did not meet primary endpoints, and further development in this area has been discontinued.

Future development efforts for XIAFLEX are likely to focus on optimizing its current indications, such as exploring new formulations or delivery methods, and potentially seeking approval in additional geographic markets where it is not yet available. However, the primary focus of R&D investment may shift towards pipeline assets with novel mechanisms of action, especially given the impending biosimilar threat to XIAFLEX. The current pipeline is not extensively detailed publicly beyond existing approved indications.

What are the manufacturing and supply chain considerations for XIAFLEX?

XIAFLEX is a biologic drug produced through a complex fermentation and purification process. Its manufacturing is conducted at specialized facilities to ensure product quality, consistency, and regulatory compliance. The supply chain involves sourcing raw materials, active pharmaceutical ingredient (API) production, fill-finish operations, and distribution to global markets.

Key manufacturing considerations include:

• Batch Consistency: Ensuring uniform potency and purity across manufacturing batches is crucial for biologics.
• Capacity Management: Maintaining sufficient manufacturing capacity to meet market demand, especially as theADELPHIA indication grows.
• Quality Control: Rigorous testing and validation at multiple stages of the production process.
• Cold Chain Logistics: As a protein-based therapeutic, XIAFLEX may require specific temperature-controlled storage and transportation to maintain its efficacy and stability throughout the supply chain.

Disruptions in the supply chain, such as raw material shortages, manufacturing issues, or logistical challenges, could impact the availability of XIAFLEX and affect sales. The company typically maintains inventory buffers and has established relationships with contract manufacturing organizations (CMOs) for specialized production steps, which can provide some resilience. The increasing focus on biologics manufacturing also means that specialized CMOs are in high demand, potentially affecting lead times and costs.

Key Takeaways

• XIAFLEX generated $206.4 million in net sales in 2023, with projected growth to $215 million-$225 million in 2024.
• The drug's revenue is driven by its established Dupuytren's contracture indication and growing adoption inADELPHIA.
• Key composition of matter patents for XIAFLEX have expired, paving the way for biosimilar competition.
• The emergence of biosimilars poses a significant long-term threat to XIAFLEX's market share and revenue.
• Manufacturing of XIAFLEX is a complex biologic process requiring specialized facilities and stringent quality control.

FAQs

1. When did the primary patents for XIAFLEX expire? The primary composition of matter patents for XIAFLEX expired in major markets, including the United States around 2018 and in Europe shortly thereafter.

2. What is the projected revenue growth for XIAFLEX in 2024? The company projects XIAFLEX net sales to be between $215 million and $225 million for fiscal year 2024, indicating a projected growth of 4.2% to 9.0% over 2023 levels.

3. Besides Dupuytren's contracture, what other indication is driving XIAFLEX sales? ADELPHIA (cellulite) is the other primary indication contributing to XIAFLEX sales, representing a significant growth area for the drug.

4. What is the main competitive threat to XIAFLEX in the long term? The main long-term competitive threat to XIAFLEX is the anticipated entry of biosimilar versions of the drug following the expiration of its core patents.

5. Has XIAFLEX been explored for other medical conditions? Yes, XIAFLEX was explored for Peyronie's disease, but further development was discontinued due to clinical trial results not meeting primary endpoints.

---

Citations

1. [Company Name]. (2023). [Company Name] Annual Report 2022. Retrieved from [URL or repository where report is accessible]
2. [Company Name]. (2024). [Company Name] Annual Report 2023. Retrieved from [URL or repository where report is accessible]
3. [Company Name]. (2024, [Month]). [Investor Presentation/Earnings Call Transcript Title]. Retrieved from [URL or repository where presentation/transcript is accessible]